https://www.profitconfidential.com/stock/valeant-huge-deals-boosted-vrx-stock/ Valeant: These Are the Huge Deals That Boosted VRX Stock Stephen Karmazyn Profit Confidential 2017-01-10T14:25:04Z 2017-07-02 03:07:40 Valeant PharmaceuticalsNYSE:VRXValeantVRX stockValeant Pharmaceuticals Intl Inc (NYSE:VRX) stock is up 6.6% after selling three brands to L'Oreal and one of its pharmaceutical divisions to Sanpower. Stock,Valeant Stock https://www.profitconfidential.com/wp-content/uploads/2017/01/valeant-stock-300x226.jpg

Valeant's Sell-Offs to L'Oreal and Sanpower Boosted VRX Stock

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is starting 2017 off on a good note, with VRX stock up over six percent by early afternoon trading on Tuesday. The boost came as a result of several big sales that the company was able to make, giving the embattled Valeant some much-needed relief.Valeant sold its "CeraVe," "AcneFree," and "AMBI" skincare brands to L'Oreal SA (EPA:OR) for $1.3 billion in cash. VRX stock also got a boost out of a solid $820.0 million deal to sell Dendreon Pharmaceuticals to Sanpower Group Co. The Sanpower deal is centered around "Provenge," a prostate cancer vaccine.“We are pleased to take this step forward in our divestiture program and are continuing to evaluate transactions to simplify our business and strengthen our balance sheet,” said Valeant CEO Joseph C. Papa. (Source: "Valeant sells cancer vaccine to China’s Sanpower Group for $819.9M," Montreal Gazette, January 10, 2017.)And if that wasn't enough good news, the company announced positive results from a second confirmatory phase three test for a lotion for the treatment of plaque psoriasis. (Source: "Pre-Open Stock Movers 01/10: (GNVC) (ILMN) (VRX) Higher; (ASNA) (WMB) (FRSH) Lower (more...)," StreetInsider.com, January 10, 2017.)The first week-and-a-half of 2017 may be a small sample size so far, but the year has been kind to VRX stock all the same. Valeant stock has climbed nearly 12% since the new year, and this is a welcome change of pace for Valeant investors, who had quite the rough ride in 2016. Shares dropped by over 87% last year, as multiple investigations regarding fraud were levied against the company for—among other things—price hikes of essential medications.Several former executives are either currently being investigated or have already been charged as the case against Valeant continues.Having said all that, some still see value in VRX stock, as evidenced by Tuesday's sell-off and rally. Valeant stock boosters can only hope that 2017 has more good news in store for the company, and that 2016 will be an aberration best left in the past.

Valeant: These Are the Huge Deals That Boosted VRX Stock

By Stephen Karmazyn Published : January 10, 2017

Valeant’s Sell-Offs to L’Oreal and Sanpower Boosted VRX Stock

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is starting 2017 off on a good note, with VRX stock up over six percent by early afternoon trading on Tuesday. The boost came as a result of several big sales that the company was able to make, giving the embattled Valeant some much-needed relief.

Valeant sold its “CeraVe,” “AcneFree,” and “AMBI” skincare brands to L’Oreal SA (EPA:OR) for $1.3 billion in cash. VRX stock also got a boost out of a solid $820.0 million deal to sell Dendreon Pharmaceuticals to Sanpower Group Co. The Sanpower deal is centered around “Provenge,” a prostate cancer vaccine.

And if that wasn’t enough good news, the company announced positive results from a second confirmatory phase three test for a lotion for the treatment of plaque psoriasis. (Source: “Pre-Open Stock Movers 01/10: (GNVC) (ILMN) (VRX) Higher; (ASNA) (WMB) (FRSH) Lower (more…),” StreetInsider.com, January 10, 2017.)

The first week-and-a-half of 2017 may be a small sample size so far, but the year has been kind to VRX stock all the same. Valeant stock has climbed nearly 12% since the new year, and this is a welcome change of pace for Valeant investors, who had quite the rough ride in 2016. Shares dropped by over 87% last year, as multiple investigations regarding fraud were levied against the company for—among other things—price hikes of essential medications.

Several former executives are either currently being investigated or have already been charged as the case against Valeant continues.

Having said all that, some still see value in VRX stock, as evidenced by Tuesday’s sell-off and rally. Valeant stock boosters can only hope that 2017 has more good news in store for the company, and that 2016 will be an aberration best left in the past.

Dear Reader: There is no magic formula to getting rich. Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis. We are 100% independent in that we are not affiliated with any bank or brokerage house. Information contained herein, while believed to be correct, is not guaranteed as accurate. Warning: Investing often involves high risks and you can lose a lot of money. Please do not invest with money you cannot afford to lose. The opinions in this content are just that, opinions of the authors. We are a publishing company and the opinions, comments, stories, reports, advertisements and articles we publish are for informational and educational purposes only; nothing herein should be considered personalized investment advice. Before you make any investment, check with your investment professional (advisor). We urge our readers to review the financial statements and prospectus of any company they are interested in. We are not responsible for any damages or losses arising from the use of any information herein. Past performance is not a guarantee of future results. All registered trademarks are the property of their respective owners.